Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 9/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 9/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 9/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983412 | 0.81 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL14983409 | 0.75 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27511070 | 0.67 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL3136486 | 0.66 | TLR7 (0.41) | CSNK1DCSNK1E | |
| SCHEMBL25878226 | 0.65 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL12628749 | 0.63 | HCAR1 (0.49) | HCAR1FGFR1 | |
| SCHEMBL2195380 | 0.61 | HCAR1 (0.50) | HCAR1FGFR1 | |
| SCHEMBL14983404 | 0.59 | CYP2C19 (0.50) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6442172 | 0.59 | HTT (0.62) | HCAR1FGFR1 | |
| SCHEMBL14983403 | 0.57 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PI4KA 1826/4885PI4K2B 1290/4885PI4K2A 1526/4885 |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PI4KA 1826/4885PI4K2B 1290/4885PI4K2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.